Compare OneSpan Inc (OSPN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Tango Therapeutics Inc. — how do they compare? OneSpan Inc trades at $17.52 (market cap $670.71M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 5.6× OneSpan Inc's market cap, and OneSpan Inc pays a 2.86% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and Tango Therapeutics Inc. for 0 Days on average.
| OSPN | TNGX | |
|---|---|---|
Market Cap | $670.71M | $3.75B |
Volume | 364,626 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $18.42 | $32.90 |
52-Week Low | $10.15 | $7.50 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $639.79M | $2.77B |
Dividend Yield | 2.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $18.20, up 1.96% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with a 73.58% gross margin and consistent earnings beats, though net cash flow turned negative in 2026. Recent product innovation with DigipassONE and positive analyst coverage support the current valuation.
The outlook remains positive given strong profitability metrics and analyst consensus, but investors should monitor cash flow trends and competitive pressures in the cybersecurity sector. The stock's current valuation appears reasonable with a P/E of 10.28, offering potential upside if execution continues.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
